Marienhaus Klinikum St. Elisabeth Neuwied — Clinical Trial Site

9 Registered trials

5 Currently recruiting

Organisation

Marienhaus Klinikum St. Elisabeth Neuwied

Location

Neuwied, Germany

Identifier

ORG-100033878

Address

Friedrich-Ebert-Strasse 59, 56564, Germany

Departments

#3203
Klinik fuer Innere Medizin
Klinik für Innere Medizin - Kardiologie
Klinik für Innere Medizin - Kardiologie/Rhythmologie
Klinik für Innere Medizin-Kardiologie
Klinik für Innere Medizin, Abteilung Kardiologie und Rhytmologie
Klinik für Innere Medizin/ Kardiologie/ Rhythmologie #2107
N/A

Clinical trials at this site (9)

Search interface

Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting

2025-521670-34-00 Acute coronary syndrome (ST-elevation myocardial infarc 5 2026-03-04
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29